Yu Xia - 21 Oct 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Reporting relationship: Director
Issuer ticker: SMMT
Reported as of: 21 Oct 2025
Net transaction value: +$9,999,983
SEC form: 4
Accepted by SEC: 23 Oct 2025, 21:06:30 UTC
Prior SEC filing: 06 Jan 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Finerman, as Attorney-in-Fact for Yu Xia

Key filing fact

Yu Xia filed Form 4 for Summit Therapeutics Inc. (SMMT) on 23 Oct 2025.

Key facts

This page summarizes Yu Xia's Form 4 filing for Summit Therapeutics Inc. (SMMT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Oct 2025, 21:06.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: +$9,999,983.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001963544 Primary reporting owner

Xia Yu

Relationship: Director
Address: C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI
Signature: /s/ Adam Finerman, as Attorney-in-Fact for Yu Xia
Signature date: 23 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SMMT transaction

Common Stock

Purchase

Transaction value: $9,999,983
Shares: +533,617
Change %: +1.7%
Price: $18.74
Shares after: 32,057,147
Date: 21 Oct 2025
Ownership: Akeso, Inc.
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.

Footnote F2

Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.